

# **Proposed Influenza Vaccination Recommendations for 2013-14**

**Lisa Grohskopf, MD, MPH  
Influenza Division, NCIRD, CDC**

**Advisory Committee on Immunization Practices**  
June 20, 2013

# Acknowledgements

Buddy Creech  
Stephen Dreskin  
Kathy Edwards  
Chip Emmanuel  
Neal Halsey  
Donna Hummell  
Robert Wood  
Clinical Immunization Safety  
Assessment Project (CISA)

Matt Greenhawt  
John Kelso

Karen Broder  
Maria Cano  
Penina Haber  
Theresa Harrington  
Tom Shimabukuro

Joe Bresee  
Carolyn Bridges  
Nancy Cox  
Dan Jernigan  
Lyn Finelli  
Alicia Fry  
Paul Gargiullo  
Sam Graitcer  
Erin Kennedy  
Andrew Kroger  
David Shay  
Leslie Sokolow  
Ray Strikas  
Mark Thompson  
Tim Uyeki

# Updated information in 2013-14 ACIP Influenza Vaccination Statement

- ❑ **Core recommendations, recently approved vaccines, new abbreviations discussed at February 2013 meeting**
  
- ❑ **New material since February 2013**
  - Influenza vaccine virus strains selected for 2013-2014.
  - Additional new quadrivalent vaccine, Fluzone® Quadrivalent
  - Two proposed modifications to recommendations for persons with a history of egg allergy

# Influenza Vaccine Viruses for 2013-14

## □ **Trivalent vaccines:**

- an A/California/7/2009 (H1N1)-like virus,
- an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011 (A/Texas/50/2012), and
- a B/Massachusetts/2/2012-like virus (Yamagata lineage).

## □ **Quadrivalent vaccines:**

- In addition to the above, will also contain a B/Brisbane/60/2008-like virus (Victoria lineage)

## Recently-approved Influenza Vaccines

- Quadrivalent Live attenuated Influenza Vaccine (LAIV4)—Flumist<sup>®</sup> Quadrivalent (MedImmune)
- Quadrivalent Inactivated Influenza Vaccine (IIV4)—Fluarix<sup>®</sup> Quadrivalent (GSK)
- Trivalent Cell-culture based inactivated influenza vaccine (ccIIV3)—Flucelvax<sup>®</sup> (Novartis)
- Trivalent Recombinant hemagglutinin vaccine (RIV3)—FluBlok<sup>®</sup> (Protein Sciences)
- **Quadrivalent Inactivated Influenza Vaccine (IIV4)—Fluzone<sup>®</sup> Quadrivalent (Sanofi Pasteur)**

## **Fluzone® Quadrivalent (IIV4)**

- ❑ Sanofi Pasteur**
- ❑ Licensed by the FDA in June 2013**
- ❑ Indicated for persons 6 months and older**
- ❑ Available in 0.25mL and 0.5mL prefilled syringes and 0.5mL single dose vials**
- ❑ Included in table of available vaccines as an acceptable alternative to other licensed products used within indications**

# Influenza Vaccination for Persons with Egg Allergies-- Proposed Modification #1

Can the individual eat lightly  
cooked egg (e.g., scrambled egg)  
without reaction?\*†

Yes

Administer vaccine per  
usual protocol

No

After eating eggs or egg-containing  
foods, does the individual  
experience ONLY hives?

Yes

Administer RIV, if patient  
aged 18 through 49 yrs.;

OR

Administer IIV

Observe for reaction for at  
least 30 minutes following  
vaccination

No

After eating eggs or egg-containing  
foods, does the individual experience  
other symptoms such as:

- Cardiovascular changes (e.g.,  
hypotension)
- Respiratory distress (e.g.,  
wheezing)
- Gastrointestinal (e.g.,  
nausea/vomiting)
- Reaction requiring epinephrine
- Reaction requiring emergency  
medical attention

Yes

Administer RIV, if patient  
aged 18 through 49 yrs.;

OR

Refer to a physician with  
expertise in management  
of allergic conditions for  
further evaluation

# Influenza Vaccination for Persons with Egg Allergies--Proposed Modification #2

## **Addition of the following:**

“For individuals who have no known history of exposure to egg, but who are suspected of being egg-allergic on the basis of previously performed allergy testing, consultation with a physician with expertise in the management of allergic conditions should be obtained prior to vaccination.”



## **Summary of Items for Discussion or Vote**

- ❑ Addition of Fluzone Quadrivalent to the Table of available vaccines**
- ❑ Modification of the egg allergy algorithm to include RIV**
- ❑ Addition of language to address persons with no history of egg exposure but questionable allergy testing**

# Thank You!

**For more information please contact Centers for Disease Control and Prevention**

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: [cdcinfo@cdc.gov](mailto:cdcinfo@cdc.gov) Web: [www.cdc.gov](http://www.cdc.gov)

